Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -1.52% | |
| Outside Day | Range Expansion | -1.52% | |
| Gapped Up | Strength | -1.52% | |
| Up 3 Days in a Row | Strength | -1.52% | |
| 20 DMA Resistance | Bearish | -0.77% | |
| Gapped Up | Strength | -0.77% | |
| 20 DMA Resistance | Bearish | -0.69% | |
| 50 DMA Resistance | Bearish | -0.69% | |
| Gapped Up | Strength | -0.69% | |
| 50 DMA Resistance | Bearish | -0.61% |
| Alert | Time |
|---|---|
| Possible NR7 | 42 minutes ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Down 2 % | about 4 hours ago |
| Down 1% | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.56 |
| 52 Week Low | 23.14 |
| Average Volume | 495,841 |
| 200-Day Moving Average | 28.06 |
| 50-Day Moving Average | 25.62 |
| 20-Day Moving Average | 24.94 |
| 10-Day Moving Average | 25.39 |
| Average True Range | 1.14 |
| RSI (14) | 47.64 |
| ADX | 17.99 |
| +DI | 19.25 |
| -DI | 12.78 |
| Chandelier Exit (Long, 3 ATRs) | 23.55 |
| Chandelier Exit (Short, 3 ATRs) | 26.57 |
| Upper Bollinger Bands | 26.43 |
| Lower Bollinger Band | 23.45 |
| Percent B (%b) | 0.52 |
| BandWidth | 11.96 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.11 |
| MACD Histogram | 0.0172 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.72 | ||||
| Resistance 3 (R3) | 26.73 | 26.18 | 26.43 | ||
| Resistance 2 (R2) | 26.18 | 25.74 | 26.17 | 26.33 | |
| Resistance 1 (R1) | 25.58 | 25.47 | 25.31 | 25.57 | 26.24 |
| Pivot Point | 25.03 | 25.03 | 24.89 | 25.02 | 25.03 |
| Support 1 (S1) | 24.43 | 24.59 | 24.16 | 24.42 | 23.74 |
| Support 2 (S2) | 23.88 | 24.32 | 23.87 | 23.65 | |
| Support 3 (S3) | 23.28 | 23.88 | 23.55 | ||
| Support 4 (S4) | 23.27 |
